BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005;54:966-971. [PMID: 15951544 DOI: 10.1136/gut.2004.052316] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Ben-Ami Shor D, Bashi T, Lachnish J, Fridkin M, Bizzaro G, Barshak I, Blank M, Shoenfeld Y. Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. J Autoimmun 2015;56:111-7. [PMID: 25479760 DOI: 10.1016/j.jaut.2014.11.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
2 Csáki KF. Synthetic surfactant food additives can cause intestinal barrier dysfunction. Medical Hypotheses 2011;76:676-81. [DOI: 10.1016/j.mehy.2011.01.030] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
3 Pathil A, Warth A, Chamulitrat W, Stremmel W. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury. J Hepatol 2011;54:674-84. [PMID: 21146893 DOI: 10.1016/j.jhep.2010.07.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
4 Kennelly JP, Carlin S, Ju T, van der Veen JN, Nelson RC, Buteau J, Thiesen A, Richard C, Willing BP, Jacobs RL. Intestinal Phospholipid Disequilibrium Initiates an ER Stress Response That Drives Goblet Cell Necroptosis and Spontaneous Colitis in Mice. Cell Mol Gastroenterol Hepatol 2021;11:999-1021. [PMID: 33238221 DOI: 10.1016/j.jcmgh.2020.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Juritsch AF, Moreau R. Role of soybean-derived bioactive compounds in inflammatory bowel disease. Nutr Rev 2018;76:618-38. [PMID: 29800381 DOI: 10.1093/nutrit/nuy021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zahn A, Giese T, Karner M, Braun A, Hinz U, Stremmel W, Ehehalt R. Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterol 2009;9:13. [PMID: 19203362 DOI: 10.1186/1471-230X-9-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
7 Wolff MJ, Broadhurst MJ, Loke P. Helminthic therapy: improving mucosal barrier function. Trends Parasitol 2012;28:187-94. [PMID: 22464690 DOI: 10.1016/j.pt.2012.02.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
8 Michielan A, D’Incà R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm. 2015;2015:628157. [PMID: 26582965 DOI: 10.1155/2015/628157] [Cited by in Crossref: 221] [Cited by in F6Publishing: 212] [Article Influence: 31.6] [Reference Citation Analysis]
9 Braun A, Schönfeld U, Welsch T, Kadmon M, Funke B, Gotthardt D, Zahn A, Autschbach F, Kienle P, Zharnikov M, Grunze M, Stremmel W, Ehehalt R. Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis 2011;26:989-98. [PMID: 21455745 DOI: 10.1007/s00384-011-1190-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
10 Caretti A, Vasso M, Bonezzi FT, Gallina A, Trinchera M, Rossi A, Adami R, Casas J, Falleni M, Tosi D, Bragonzi A, Ghidoni R, Gelfi C, Signorelli P. Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids. Naunyn Schmiedebergs Arch Pharmacol 2017;390:775-90. [PMID: 28439630 DOI: 10.1007/s00210-017-1373-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Yeshi K, Creek DJ, Anderson D, Ritmejerytė E, Becker L, Loukas A, Wangchuk P. Metabolomes and Lipidomes of the Infective Stages of the Gastrointestinal nematodes, Nippostrongylus brasiliensis and Trichuris muris. Metabolites 2020;10:E446. [PMID: 33171998 DOI: 10.3390/metabo10110446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw 2017;17:25-40. [PMID: 28261018 DOI: 10.4110/in.2017.17.1.25] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 25.8] [Reference Citation Analysis]
13 Stremmel W, Schmidt KV, Schuhmann V, Kratzer F, Garbade SF, Langhans CD, Fricker G, Okun JG. Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. PLoS One 2017;12:e0170742. [PMID: 28129384 DOI: 10.1371/journal.pone.0170742] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
14 Chen L, Xu K, Gui Q, Chen Y, Chen D, Yang Y. Probiotic pre-administration reduces mortality in a mouse model of cecal ligation and puncture-induced sepsis. Exp Ther Med 2016;12:1836-42. [PMID: 27588102 DOI: 10.3892/etm.2016.3534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kaser A, Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opinion on Therapeutic Targets 2008;12:553-63. [DOI: 10.1517/14728222.12.5.553] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
16 Meletis CD, Zabriskie N. Supporting Gastrointestinal Health with Nutritional Therapy. Alternative and Complementary Therapies 2008;14:132-8. [DOI: 10.1089/act.2008.14305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Narula N, Rubin DT, Sands BE. Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. Am J Gastroenterol Suppl 2016;3:38-44. [DOI: 10.1038/ajgsup.2016.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Moreau GB, Ramakrishnan G, Cook HL, Fox TE, Nayak U, Ma JZ, Colgate ER, Kirkpatrick BD, Haque R, Petri WA Jr. Childhood growth and neurocognition are associated with distinct sets of metabolites. EBioMedicine 2019;44:597-606. [PMID: 31133540 DOI: 10.1016/j.ebiom.2019.05.043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
19 Stremmel W, Staffer S, Stuhrmann N, Gan-Schreier H, Gauss A, Burger N, Hornuss D. Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors. Inflamm Intest Dis 2018;2:180-7. [PMID: 29922677 DOI: 10.1159/000486858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gotthardt D, Braun A, Tietje A, Weiss KH, Ehehalt R, Stremmel WR. Separate basolateral and apical phosphatidylcholine secretion routes in intestinally differentiated tumor cells. World J Gastroenterol 2009; 15(46): 5821-5826 [PMID: 19998503 DOI: 10.3748/wjg.15.5821] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Bamias G, Pizarro TT, Cominelli F. Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res 2016;167:104-15. [PMID: 26408803 DOI: 10.1016/j.trsl.2015.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
22 Raine T. Insights from immunology: new targets for new drugs? Best Pract Res Clin Gastroenterol 2014;28:411-20. [PMID: 24913381 DOI: 10.1016/j.bpg.2014.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Markovic M, Ben-Shabat S, Aponick A, Zimmermann EM, Dahan A. Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics. Int J Mol Sci 2020;21:E3248. [PMID: 32375338 DOI: 10.3390/ijms21093248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Tyagi P, Kashyap M, Hensley H, Yoshimura N. Advances in intravesical therapy for urinary tract disorders. Expert Opin Drug Deliv 2016;13:71-84. [PMID: 26479968 DOI: 10.1517/17425247.2016.1100166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
25 Khan MW, Kale AA, Bere P, Vajjala S, Gounaris E, Pakanati KC. Microbes, intestinal inflammation and probiotics. Expert Rev Gastroenterol Hepatol. 2012;6:81-94. [PMID: 22149584 DOI: 10.1586/egh.11.94] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
26 Stremmel W, Weiskirchen R, Melnik BC. Milk Exosomes Prevent Intestinal Inflammation in a Genetic Mouse Model of Ulcerative Colitis: A Pilot Experiment. Inflamm Intest Dis 2020;5:117-23. [PMID: 32999884 DOI: 10.1159/000507626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
27 Baird AC, Lloyd F, Lawrance IC. Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function. Dig Dis Sci 2015;60:1603-16. [PMID: 25630423 DOI: 10.1007/s10620-015-3552-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Parlesak A, Schaeckeler S, Moser L, Bode C. Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production: . Critical Care Medicine 2007;35:2367-74. [DOI: 10.1097/01.ccm.0000284586.84952.fb] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
29 Inaba M, Murota K, Nikawadori M, Kishino E, Matusda R, Takagi M, Ohkubo T, Tanaka T, Terao J, Tokumura A. Extracellular metabolism-dependent uptake of lysolipids through cultured monolayer of differentiated Caco-2 cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2014;1841:121-31. [DOI: 10.1016/j.bbalip.2013.10.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
30 Parian AM, Mullin GE, Langhorst J, Brown AC. Inflammatory Bowel Disease. Integrative Medicine. Elsevier; 2018. pp. 501-516.e8. [DOI: 10.1016/b978-0-323-35868-2.00050-5] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Travis S. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005;7:475-484. [PMID: 16313878 DOI: 10.1007/s11894-005-0079-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
32 Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease: Review: Innate immune dysfunction in IBD. Journal of Internal Medicine 2012;271:421-8. [DOI: 10.1111/j.1365-2796.2012.02515.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 9.7] [Reference Citation Analysis]
33 Lee WC, Chuang YC, Lee WC, Chiang PH. Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci 2011;27:437-40. [PMID: 21943815 DOI: 10.1016/j.kjms.2011.06.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
34 Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330 [PMID: 30598577 DOI: 10.3748/wjg.v24.i47.5322] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
35 Komalla V, Allam VSRR, Kwok PCL, Sheikholeslami B, Owen L, Jaffe A, Waters SA, Mohammad S, Oliver BG, Chen H, Haghi M. A phospholipid-based formulation for the treatment of airway inflammation in chronic respiratory diseases. Eur J Pharm Biopharm 2020;157:47-58. [PMID: 33065219 DOI: 10.1016/j.ejpb.2020.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Stremmel W, Lukasova M, Weiskirchen R. The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article. Ann Transl Med 2021;9:738. [PMID: 33987436 DOI: 10.21037/atm-20-3591] [Reference Citation Analysis]
38 Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. [PMID: 17934839 DOI: 10.1007/s10620-007-9954-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
39 Amadei F, Fröhlich B, Stremmel W, Tanaka M. Nonclassical Interactions of Phosphatidylcholine with Mucin Protect Intestinal Surfaces: A Microinterferometry Study. Langmuir 2018;34:14046-57. [PMID: 30359036 DOI: 10.1021/acs.langmuir.8b03035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Ayeni FA, Biagi E, Rampelli S, Fiori J, Soverini M, Audu HJ, Cristino S, Caporali L, Schnorr SL, Carelli V, Brigidi P, Candela M, Turroni S. Infant and Adult Gut Microbiome and Metabolome in Rural Bassa and Urban Settlers from Nigeria. Cell Reports 2018;23:3056-67. [DOI: 10.1016/j.celrep.2018.05.018] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 17.0] [Reference Citation Analysis]
41 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
42 Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I. Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1718-29. [PMID: 28885228 DOI: 10.1097/MIB.0000000000001246] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
43 Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol 2010;44:e101-7. [PMID: 20048683 DOI: 10.1097/MCG.0b013e3181c29860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
44 Stremmel W, Staffer S, Schneider MJ, Gan-Schreier H, Wannhoff A, Stuhrmann N, Gauss A, Wolburg H, Mahringer A, Swidsinski A, Efferth T. Genetic Mouse Models with Intestinal-Specific Tight Junction Deletion Resemble an Ulcerative Colitis Phenotype. J Crohns Colitis 2017;11:1247-57. [PMID: 28575164 DOI: 10.1093/ecco-jcc/jjx075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
45 Küllenberg D, Taylor LA, Schneider M, Massing U. Health effects of dietary phospholipids. Lipids Health Dis 2012;11:3. [PMID: 22221489 DOI: 10.1186/1476-511X-11-3] [Cited by in Crossref: 269] [Cited by in F6Publishing: 75] [Article Influence: 26.9] [Reference Citation Analysis]
46 Chittim CL, Martínez del Campo A, Balskus EP. Gut bacterial phospholipase Ds support disease-associated metabolism by generating choline. Nat Microbiol 2019;4:155-63. [DOI: 10.1038/s41564-018-0294-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
47 Ng SC, Kamm MA. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2008;28:815-29. [DOI: 10.1111/j.1365-2036.2008.03800.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
48 Rogler G. Where are we heading to in pharmacological IBD therapy? Pharmacol Res. 2015;100:220-227. [PMID: 26277232 DOI: 10.1016/j.phrs.2015.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
49 Tyagi P, Kashyap M, Majima T, Kawamorita N, Yoshizawa T, Yoshimura N. Intravesical liposome therapy for interstitial cystitis. Int J Urol 2017;24:262-71. [DOI: 10.1111/iju.13317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
50 Treede I, Braun A, Jeliaskova P, Giese T, Füllekrug J, Griffiths G, Stremmel W, Ehehalt R. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol 2009;9:53. [PMID: 19594939 DOI: 10.1186/1471-230X-9-53] [Cited by in Crossref: 60] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
51 Wang B, Zhuang X, Deng ZB, Jiang H, Mu J, Wang Q, Xiang X, Guo H, Zhang L, Dryden G, Yan J, Miller D, Zhang HG. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther 2014;22:522-34. [PMID: 23939022 DOI: 10.1038/mt.2013.190] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 12.6] [Reference Citation Analysis]
52 Wooster TJ, Acquistapace S, Mettraux C, Donato L, Dekkers BL. Hierarchically structured phase separated biopolymer hydrogels create tailorable delayed burst release during gastrointestinal digestion. J Colloid Interface Sci 2019;553:308-19. [PMID: 31212230 DOI: 10.1016/j.jcis.2019.06.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
53 Kikut J, Konecka N, Ziętek M, Kulpa D, Szczuko M. Diet supporting therapy for inflammatory bowel diseases. Eur J Nutr 2021;60:2275-91. [PMID: 33788019 DOI: 10.1007/s00394-021-02489-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Treede I, Braun A, Sparla R, Kühnel M, Giese T, Turner JR, Anes E, Kulaksiz H, Füllekrug J, Stremmel W, Griffiths G, Ehehalt R. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 2007;282:27155-64. [PMID: 17636253 DOI: 10.1074/jbc.M704408200] [Cited by in Crossref: 144] [Cited by in F6Publishing: 62] [Article Influence: 9.6] [Reference Citation Analysis]
55 Vasconcelos PC, Seito LN, Di Stasi LC, Akiko Hiruma-Lima C, Pellizzon CH. Epicatechin used in the treatment of intestinal inflammatory disease: an analysis by experimental models. Evid Based Complement Alternat Med 2012;2012:508902. [PMID: 23346204 DOI: 10.1155/2012/508902] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
56 Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W, Pathil A. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. Nutrients. 2018;10. [PMID: 29883377 DOI: 10.3390/nu10050649] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
57 Bjørkkjaer T, Brun JG, Valen M, Arslan G, Lind R, Brunborg LA, Berstad A, Frøyland L. Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease. Lipids Health Dis 2006;5:6. [PMID: 16549021 DOI: 10.1186/1476-511X-5-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
58 Pandey NR, Sultan K, Twomey E, Sparks DL. Phospholipids block nuclear factor-kappa B and tau phosphorylation and inhibit amyloid-beta secretion in human neuroblastoma cells. Neuroscience 2009;164:1744-53. [PMID: 19788916 DOI: 10.1016/j.neuroscience.2009.09.062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
59 Schneider H, Braun A, Füllekrug J, Stremmel W, Ehehalt R. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int J Mol Sci 2010;11:4149-64. [PMID: 21152327 DOI: 10.3390/ijms11104149] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
60 Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, Loke P. IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med. 2010;2:60ra88. [PMID: 21123809 DOI: 10.1126/scitranslmed.3001500] [Cited by in Crossref: 146] [Cited by in F6Publishing: 131] [Article Influence: 13.3] [Reference Citation Analysis]
61 Davies JM, Hua HU, Dheer R, Martinez M, Bhattacharya SK, Abreu MT. Stool phospholipid signature is altered by diet and tumors. PLoS One 2014;9:e114352. [PMID: 25469718 DOI: 10.1371/journal.pone.0114352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
62 Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2017;2:521-30. [PMID: 28606878 DOI: 10.1016/S2468-1253(17)30031-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
63 Ehehalt R, Krautter M, Zorn M, Sparla R, Füllekrug J, Kulaksiz H, Stremmel W. Increased basolateral sorting of carcinoembryonic antigen in a polarized colon carcinoma cell line after cholesterol depletion-Implications for treatment of inflammatory bowel disease. World J Gastroenterol 2008; 14(10): 1528-1533 [PMID: 18330942 DOI: 10.3748/wjg.14.1528] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
64 Kovács T, Varga G, Erces D, Tőkés T, Tiszlavicz L, Ghyczy M, Vécsei L, Boros M, Kaszaki J. [Comparative study of novel therapeutic possibilities in animal experimental model of inflammatory bowel disease]. Magy Seb 2012;65:191-7. [PMID: 22940387 DOI: 10.1556/MaSeb.65.2012.4.4] [Reference Citation Analysis]
65 Ju T, Kennelly JP, Jacobs RL, Willing BP. Insufficient dietary choline aggravates disease severity in a mouse model of Citrobacter rodentium-induced colitis. Br J Nutr 2021;125:50-61. [PMID: 32792032 DOI: 10.1017/S0007114520002639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Olivera P, Danese S, Peyrin-biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 12.0] [Reference Citation Analysis]
67 Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut. 2013;62:1642-1652. [PMID: 24104885 DOI: 10.1136/gutjnl-2012-303959] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
68 Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann W, Fuellekrug J, Stremmel W, Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis: . Inflammatory Bowel Diseases 2009;15:1705-20. [DOI: 10.1002/ibd.20993] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 7.5] [Reference Citation Analysis]
69 Stremmel W, Ehehalt R, Staffer S, Stoffels S, Mohr A, Karner M, Braun A. Mucosal protection by phosphatidylcholine. Dig Dis. 2012;30 Suppl 3:85-91. [PMID: 23295697 DOI: 10.1159/000342729] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
70 Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 2009;50:143-54. [PMID: 19496180 DOI: 10.1002/hep.22955] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
71 Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W. Phosphatidylcholine as a constituent in the colonic mucosal barrier--physiological and clinical relevance. Biochim Biophys Acta 2010;1801:983-93. [PMID: 20595010 DOI: 10.1016/j.bbalip.2010.05.014] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
72 Turroni S, Fiori J, Rampelli S, Schnorr SL, Consolandi C, Barone M, Biagi E, Fanelli F, Mezzullo M, Crittenden AN, Henry AG, Brigidi P, Candela M. Fecal metabolome of the Hadza hunter-gatherers: a host-microbiome integrative view. Sci Rep 2016;6:32826. [PMID: 27624970 DOI: 10.1038/srep32826] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
73 Dial EJ, Zayat M, Lopez-storey M, Tran D, Lichtenberger L. ORAL PHOSPHATIDYLCHOLINE PRESERVES THE GASTROINTESTINAL MUCOSAL BARRIER DURING LPS-INDUCED INFLAMMATION. Shock 2008;30:729-33. [DOI: 10.1097/shk.0b013e318173e8d4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
74 Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19. [PMID: 24084775 DOI: 10.1038/mi.2013.73] [Cited by in Crossref: 192] [Cited by in F6Publishing: 188] [Article Influence: 21.3] [Reference Citation Analysis]
75 Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut. 2005;54:900-903. [PMID: 15951531 DOI: 10.1136/gut.2004.058453] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
76 Jung HJ, Moon JS, Park AR, Choi H, Lee JE, Choi SH, Lim CJ. Anti-inflammatory, antinociceptive and anti-angiogenic activities of a phospholipid mixture purified from porcine lung tissues. Immunopharmacol Immunotoxicol 2012;34:398-407. [PMID: 21981117 DOI: 10.3109/08923973.2011.611137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
77 van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017;1859:1558-1572. [PMID: 28411170 DOI: 10.1016/j.bbamem.2017.04.006] [Cited by in Crossref: 298] [Cited by in F6Publishing: 280] [Article Influence: 59.6] [Reference Citation Analysis]
78 Boldyreva LV, Morozova MV, Saydakova SS, Kozhevnikova EN. Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:11682. [PMID: 34769112 DOI: 10.3390/ijms222111682] [Reference Citation Analysis]
79 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
80 Andersen CJ. Bioactive Egg Components and Inflammation. Nutrients 2015;7:7889-913. [PMID: 26389951 DOI: 10.3390/nu7095372] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 8.9] [Reference Citation Analysis]
81 Asama M, Hall A, Qi Y, Moreau B, Walthier H, Schaschwary M, Bristow B, Wang Q. Alternative foaming agents for topical treatment of ulcerative colitis. J Biomed Mater Res A 2018;106:1448-56. [PMID: 29314587 DOI: 10.1002/jbm.a.36324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
82 Scholmerich J. Inflammatory Bowel Disease: Pandora's Box, Present and Future. Annals of the New York Academy of Sciences 2006;1072:365-78. [DOI: 10.1196/annals.1326.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
83 Zahn A, Hinz U, Karner M, Ehehalt R, Stremmel W. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:1058-1067. [PMID: 17075347 DOI: 10.1097/01.mib.0000234134.35713.d2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
84 Cetinkaya M, Cansev M, Cekmez F, Tayman C, Canpolat FE, Kafa IM, Uysal S, Tunc T, Sarici SU. CDP-choline reduces severity of intestinal injury in a neonatal rat model of necrotizing enterocolitis. J Surg Res 2013;183:119-28. [PMID: 23228325 DOI: 10.1016/j.jss.2012.11.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
85 Bock J, Liebisch G, Schweimer J, Schmitz G, Rogler G. Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World J Gastroenterol 2007; 13(39): 5217-5225 [PMID: 17876892 DOI: 10.3748/wjg.v13.i39.5217] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
86 Kovács T, Varga G, Érces D, Tőkés T, Tiszlavicz L, Ghyczy M, Boros M, Kaszaki J. Dietary Phosphatidylcholine Supplementation Attenuates Inflammatory Mucosal Damage in a Rat Model of Experimental Colitis. Shock 2012;38:177-85. [DOI: 10.1097/shk.0b013e31825d1ed0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
87 Stange EF, Schroeder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol. 2019;13:963-976. [PMID: 31603356 DOI: 10.1080/17474124.2019.1671822] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
88 Esteban-Zubero E, López-Pingarrón L, Alatorre-Jiménez MA, Ochoa-Moneo P, Buisac-Ramón C, Rivas-Jiménez M, Castán-Ruiz S, Antoñanzas-Lombarte Á, Tan DX, García JJ, Reiter RJ. Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. Life Sci 2017;170:72-81. [PMID: 27919824 DOI: 10.1016/j.lfs.2016.11.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
89 Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013;4:280. [PMID: 24062746 DOI: 10.3389/fimmu.2013.00280] [Cited by in Crossref: 245] [Cited by in F6Publishing: 237] [Article Influence: 27.2] [Reference Citation Analysis]
90 Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
91 Gauss A, Buchholz I, Zahn A, Schmitz G, Stremmel W, Fuellekrug J, Ehehalt R. Flotillin-2 expression in the human gut: from a cell model to human tissue in health and inflammatory bowel diseases. Int J Med Sci 2013;10:1259-70. [PMID: 23983584 DOI: 10.7150/ijms.6358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 Ran ZH, Chen C, Xiao SD. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomedicine & Pharmacotherapy 2008;62:189-96. [DOI: 10.1016/j.biopha.2008.02.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
93 Hassan MA, Tamer TM, Valachová K, Omer AM, El-Shafeey M, Mohy Eldin MS, Šoltés L. Antioxidant and antibacterial polyelectrolyte wound dressing based on chitosan/hyaluronan/phosphatidylcholine dihydroquercetin. Int J Biol Macromol 2021;166:18-31. [PMID: 33220372 DOI: 10.1016/j.ijbiomac.2020.11.119] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
94 Bauer J, Liebisch G, Hofmann C, Huy C, Schmitz G, Obermeier F, Bock J. Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression. PLoS One 2009;4:e7197. [PMID: 19787068 DOI: 10.1371/journal.pone.0007197] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
95 Sarvarian P, Samadi P, Gholipour E, Shams Asenjan K, Hojjat-Farsangi M, Motavalli R, Motavalli Khiavi F, Yousefi M. Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems. Immunol Invest 2021;:1-21. [PMID: 33627016 DOI: 10.1080/08820139.2021.1891094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Nilsson Å. Optimizing management of distal ulcerative colitis. Scandinavian Journal of Gastroenterology 2009;41:511-23. [DOI: 10.1080/00365520600575738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
97 Stremmel W, Staffer S, Gehrke S. The Detergent Effect of Mesalazine Interferes with Phosphatidylcholine Binding to Mucin 2. Inflamm Intest Dis 2019;3:107-15. [PMID: 30820432 DOI: 10.1159/000493347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
98 Rondanelli M, Lamburghini S, Faliva MA, Peroni G, Riva A, Allegrini P, Spadaccini D, Gasparri C, Iannello G, Infantino V, Alalwan TA, Perna S, Miccono A. A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease. Endocrinol Diabetes Nutr (Engl Ed) 2021;68:17-46. [PMID: 32499202 DOI: 10.1016/j.endinu.2020.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W. First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol. 2014;109:1041-1051. [PMID: 24796768 DOI: 10.1038/ajg.2014.104] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]